# US 2019/0290588 A1 · Stable bilayer tablet compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290588 A1
- Document ID: US20190290588A1
- Status: Published application
- Kind: A1
- Application number: 16/103,615
- Filed: 2018-08-14
- Published: 2019-09-26
- Earliest claimed: 2018-03-26
- Assignees: Hetero Labs Limited
- Applicants: Hetero Labs Limited
- Inventors: Parthasaradhi Reddy BANDI; Khadgapathi Podile; Sunil Deviprasad Tiwari; Srinivasa Rao Gella
- Web page: https://patentgrep.com/patent/US20190290588A1

## CPC

- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/2095: {Tabletting processes}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A stable bilayer tablet composition comprising:
(i) 10 mg to 25 mg of empagliflozin;
(ii) 5 mg of linagliptin; and
(iii) at least one pharmaceutically acceptable excipient;
wherein the amount of empagliflozin is 1% to 20% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 10% (w/w) based on total weight of the composition.

### Claim 12 (depends on 1)

The composition according to claim 1, comprising:
(i) 10 mg of empagliflozin;
(ii) 5 mg of linagliptin; and
(iii) at least one pharmaceutically acceptable excipient;
wherein the amount of empagliflozin is 3% to 10% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 6% (w/w) based on total weight of the composition.

### Claim 13 (depends on 1)

The composition according to claim 1, comprising:
(i) 25 mg of empagliflozin;
(ii) 5 mg of linagliptin; and
(iii) at least one pharmaceutically acceptable excipient;
wherein the amount of empagliflozin is 8% to 16% (w/w) based on total weight of the composition and the amount of linagliptin is 1% to 6% (w/w) based on total weight of the composition.

### Claim 14 (depends on 1)

The composition according to claim 1, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium.

### Claim 15

A stable bilayer tablet composition comprising:
(i) empagliflozin;
(ii) linagliptin;
(iii) 5% to 30% (w/w) of microcrystalline cellulose;
(iv) 10-40% (w/w) of lactose monohydrate; and
(v) 0.5% to 5% (w/w) of croscarmellose sodium based on total weight of the composition.

### Claim 16 (depends on 5)

The composition according to claim 5, wherein
(i) the amount of microcrystalline cellulose is 10% to 25% (w/w) based on total weight of the composition; and
(ii) the amount of lactose monohydrate is 20% to 30% (w/w) based on total weight of the composition.

### Claim 17 (depends on 1)

The composition according to claim 1, wherein the composition exhibits dissolution of more than 85% of empagliflozin and linagliptin within 15 minutes in a dissolution test using USP paddle type dissolution apparatus.

### Claim 18 (depends on 1)

The composition according to claim 1, wherein the composition is an immediate release tablet.

### Claim 19 (depends on 1)

The composition according to claim 1, wherein the composition is prepared by wet granulation method.

### Claim 20

A stable bilayer tablet composition comprising:
(i) 10 mg to 25 mg of empagliflozin; and
(ii) 5 mg of linagliptin;
